Lynch & Associates IN grew its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 3.8% during the second quarter, HoldingsChannel reports. The firm owned 73,746 shares of the company’s stock after buying an additional 2,731 shares during the period. AbbVie comprises approximately 2.8% of Lynch & Associates IN’s portfolio, making the stock its 8th largest holding. Lynch & Associates IN’s holdings in AbbVie were worth $12,649,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of ABBV. Anchor Capital Advisors LLC boosted its position in shares of AbbVie by 0.7% during the 2nd quarter. Anchor Capital Advisors LLC now owns 96,566 shares of the company’s stock valued at $16,563,000 after purchasing an additional 703 shares in the last quarter. Certuity LLC boosted its holdings in shares of AbbVie by 10.0% during the 2nd quarter. Certuity LLC now owns 6,775 shares of the company’s stock worth $1,162,000 after buying an additional 615 shares in the last quarter. Kerusso Capital Management LLC bought a new position in shares of AbbVie during the 2nd quarter worth approximately $1,072,000. Counterweight Ventures LLC increased its stake in shares of AbbVie by 0.6% in the 2nd quarter. Counterweight Ventures LLC now owns 16,448 shares of the company’s stock valued at $2,821,000 after acquiring an additional 96 shares in the last quarter. Finally, Chris Bulman Inc acquired a new position in shares of AbbVie during the 2nd quarter valued at $420,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.
AbbVie Stock Performance
Shares of ABBV stock opened at $193.40 on Friday. The company has a debt-to-equity ratio of 8.51, a current ratio of 0.81 and a quick ratio of 0.71. The firm has a 50-day moving average of $183.88 and a 200-day moving average of $174.60. AbbVie Inc. has a one year low of $135.85 and a one year high of $199.95. The company has a market cap of $341.52 billion, a P/E ratio of 57.39, a P/E/G ratio of 2.68 and a beta of 0.64.
AbbVie Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be given a $1.55 dividend. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $6.20 annualized dividend and a yield of 3.21%. AbbVie’s dividend payout ratio is currently 183.98%.
Wall Street Analysts Forecast Growth
A number of research firms have commented on ABBV. William Blair upgraded shares of AbbVie to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 target price on shares of AbbVie in a research note on Monday, August 5th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Wednesday, June 5th. Piper Sandler raised their price objective on AbbVie from $196.00 to $209.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Finally, Wells Fargo & Company upped their target price on AbbVie from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Friday, July 26th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, AbbVie presently has an average rating of “Buy” and an average price target of $191.64.
Read Our Latest Report on ABBV
Insider Activity
In other AbbVie news, Chairman Richard A. Gonzalez sold 282,845 shares of AbbVie stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $175.00, for a total value of $49,497,875.00. Following the sale, the chairman now owns 513,099 shares of the company’s stock, valued at $89,792,325. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other AbbVie news, Chairman Richard A. Gonzalez sold 282,845 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.00. Following the completion of the transaction, the chairman now directly owns 513,099 shares of the company’s stock, valued at $89,792,325. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Richard A. Gonzalez sold 66,500 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.00. Following the completion of the sale, the chairman now owns 446,599 shares in the company, valued at $83,299,645.48. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also
- Five stocks we like better than AbbVie
- What Are the U.K. Market Holidays? How to Invest and Trade
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- How Technical Indicators Can Help You Find Oversold Stocks
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Options Trading – Understanding Strike Price
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.